Venereal Disease Research Laboratory test
A test for syphilis
The Venereal Disease Research Laboratory test (VDRL test) is a blood test for syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum. The test detects non-specific antibodies that the body produces in response to the infection.
Principle
The VDRL test is a type of flocculation test that detects the presence of reagin antibodies in the blood. These antibodies are not specific to Treponema pallidum but are produced in response to cellular damage caused by the infection. The test involves mixing the patient's serum with a cardiolipin-lecithin-cholesterol antigen. If reagin antibodies are present, they will bind to the antigen and form visible clumps, indicating a positive result.
Procedure
The VDRL test is performed by collecting a blood sample from the patient. The serum is separated from the blood cells and mixed with the antigen on a slide. The slide is then observed under a microscope for the presence of clumping, which indicates a positive reaction.
Interpretation of Results
A positive VDRL test indicates the presence of reagin antibodies, which may suggest a syphilis infection. However, because the test is non-specific, it can also yield false-positive results in conditions such as lupus, malaria, and certain viral infections. Therefore, a positive VDRL test is usually confirmed with a more specific test, such as the Fluorescent Treponemal Antibody Absorption Test (FTA-ABS).
Limitations
The VDRL test is less sensitive in the early stages of syphilis and in late latent syphilis. It is also subject to false-positive results due to other medical conditions. Therefore, it is often used as a screening test, with positive results confirmed by more specific tests.
Clinical Use
The VDRL test is commonly used for screening blood donors and pregnant women for syphilis. It is also used to monitor the effectiveness of treatment in patients diagnosed with syphilis, as the antibody levels typically decrease with successful treatment.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD